Earnings release
Page 1
For personal use only 28 October 2021 ASX ANNOUNCEMENT impedimedⓇ QUARTERLY ACTIVITIES REPORT APPENDIX 4C - Quarter Ended 30 September 2021 ( Q1 FY'22 ) ImpediMed Limited ( ASX.IPD ) today released its Appendix 4C - Quarterly Cash Flow report for the period ended 30 September 2021. A summary of the quarterly results was released on 27 October 2021 as part of the Capital Raising Presentation . Highlights Quarterly Results Total Revenue for Q1 FY'22 of $ 2.6 million , + 71 % on the previous corresponding period ( pcp ) . Record quarter for SOZOⓇ Revenue for Q1 FY'22 of $ 2.5 million , + 76 % pcp . Record quarter for cash receipts of $ 2.5 million . Largest US customer renewed SOZO agreement for an additional 3 years , integrating SOZO into their EPIC EHR system . Corporate Accounts : ○ ICON Group contract for initial 13 units . о Advocate Aurora Health imitated Heart Failure program . Subsequent Events • PREVENT Results Released : ○ Primary endpoint met with statistical and clinical significance achieved . AstraZeneca ( AZ ) contract extension and expansion – estimated value of over $ 500k in additional revenue to be recognised in coming quarters . Capital Raising : O $ 35 million Placement to new and existing institutional and sophisticated investors , increasing the pro forma cash balance to approximately $ 48 million , net of fees . о ○ Sufficient capital raised to achieve breakeven while still allowing for investment in key growth initiatives . Additional $ 5 million Share Purchase Plan ( SPP ) announced for eligible shareholders . Revenue Summary : • • Total Revenue for Q1 FY'22 of $ 2.6 million , + 71 % pcp ( Q1 FY’21 : $ 1.5 million ) and + 1 % quarter over quarter . Record quarter for SOZOⓇ Revenue for Q1 FY'22 of $ 2.5 million , + 76 % pcp ( Q1 FY'21 : $ 1.4 million ) and + 8 % quarter over quarter . Record quarter for SOZO SaaS Revenue for Q1 FY'22 of $ 2.1 million , + 95 % pcp and + 10 % quarter over quarter . о SOZO SaaS Revenue of $ 1.3 million from Core Business ' . O SOZO SaaS Revenue of $ 0.8 million from Clinical Business " .